WAT (Waters Corp)
Insider Trading Activity
Every open-market purchase and sale reported by WAT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-07 | CHRISTOPHER A KUEBLER | Director | MIXED | — | — |
| 2026-08-07 | CHRISTOPHER A KUEBLER | Director | MIXED | — | — |
| 2026-07-02 | Wei Jiang | Director | A | — | — |
| 2026-07-02 | Heather Knight | Director | A | — | — |
| 2026-06-25 | Robert L Carpio III | SVP Waters Analytical Sciences | F | — | — |
| 2026-05-14 | Amol Chaubal | SVP & Chief Financial Officer | F | — | — |
| 2026-04-07 | Jianqing Bennett | SVP Waters Adv. Diagnostics | F | — | — |
| 2026-04-02 | Heather Knight | Director | A | — | — |
| 2026-04-02 | Wei Jiang | Director | A | — | — |
| 2026-03-18 | Wei Jiang | Director | Buy | — | — |
| 2026-03-10 | RICHARD H FEARON | Director | Buy | — | — |
| 2026-03-03 | Jianqing Bennett | SVP Waters Adv. Diagnostics | F | — | — |
| 2026-03-03 | Amol Chaubal | SVP & Chief Financial Officer | F | — | — |
| 2026-03-03 | Udit Batra | President and CEO | F | — | — |
| 2026-02-27 | Flemming Ornskov | Director | A | — | — |
| 2026-02-27 | LINDA BADDOUR | Director | A | — | — |
| 2026-02-27 | Daniel J. Brennan | Director | A | — | — |
| 2026-02-27 | RICHARD H FEARON | Director | A | — | — |
| 2026-02-27 | Claire Fraser | Director | A | — | — |
| 2026-02-27 | Pearl S Huang | Director | A | — | — |
| 2026-02-27 | Wei Jiang | Director | A | — | — |
| 2026-02-27 | Heather Knight | Director | A | — | — |
| 2026-02-27 | CHRISTOPHER A KUEBLER | Director | A | — | — |
| 2026-02-27 | Mark Vergnano | Director | A | — | — |
| 2026-02-27 | Udit Batra | President and CEO | A | — | — |
| 2026-02-27 | Amol Chaubal | SVP & Chief Financial Officer | A | — | — |
| 2026-02-27 | Jianqing Bennett | SVP Waters Adv. Diagnostics | A | — | — |
| 2026-02-27 | Robert L Carpio III | SVP Waters Analytical Sciences | A | — | — |
| 2026-02-06 | Udit Batra | President and CEO | MIXED | — | — |
| 2026-02-06 | Amol Chaubal | SVP & Chief Financial Officer | MIXED | — | — |
| 2026-02-06 | Jianqing Bennett | SVP TA Instruments Division | MIXED | — | — |
| 2026-02-06 | Robert L Carpio III | SVP, Waters Division | F | — | — |
| 2026-01-05 | Heather Knight | Director | A | — | — |
| 2026-01-05 | Wei Jiang | Director | A | — | — |
| 2026-01-05 | Flemming Ornskov | Director | A | — | — |
| 2026-01-05 | LINDA BADDOUR | Director | A | — | — |
| 2026-01-05 | Daniel J. Brennan | Director | A | — | — |
| 2026-01-05 | RICHARD H FEARON | Director | A | — | — |
| 2026-01-05 | Pearl S Huang | Director | A | — | — |
| 2026-01-05 | CHRISTOPHER A KUEBLER | Director | A | — | — |
| 2026-01-05 | Mark Vergnano | Director | A | — | — |
| 2025-11-07 | CHRISTOPHER A KUEBLER | Director | MIXED | — | — |
| 2025-10-02 | Wei Jiang | Director | A | — | — |
| 2025-10-02 | Heather Knight | Director | A | — | — |
| 2025-07-01 | Wei Jiang | Director | A | — | — |
| 2025-07-01 | Heather Knight | Director | A | — | — |
| 2025-06-26 | Robert L Carpio III | SVP, Waters Division | F | — | — |
| 2025-05-14 | Amol Chaubal | SVP & Chief Financial Officer | F | — | — |
| 2025-04-08 | Jianqing Bennett | SVP TA Instruments Division | F | — | — |
| 2025-04-02 | Heather Knight | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,178,295 | — |
| — | EVP and President, Waters Div | 99,743 | — |
| — | Director | 74,542 | — |
| — | Director | 60,349 | — |
| — | CEO and President | 57,595 | — |
| — | Director | 39,685 | — |
| — | Director | 34,985 | — |
| — | President and CEO | 33,140 | — |
| — | Director | 25,849 | — |
| — | Director | 21,434 | — |
| — | SVP and CFO | 21,219 | — |
| — | SVP, Global HR | 17,102 | — |
| — | Director | 16,449 | — |
| — | CFO | 11,906 | — |
| — | VP, CORP CONT & PRIN ACCT OFF | 8,760 | — |
| — | Director | 8,245 | — |
| — | SVP & Chief Financial Officer | 7,834 | — |
| — | SVP | 6,988 | — |
| — | SVP Waters Adv. Diagnostics | 6,532 | — |
| — | SVP, Global Products | 5,529 | — |
| — | Director | 5,271 | — |
| — | Director | 4,540 | — |
| — | SVP Waters Division | 4,263 | — |
| — | SVP and General Counsel | 4,090 | — |
| — | Director | 4,067 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the WAT quote page; the site-wide leaderboard is on the insider transactions hub.